Prognosis
The Dark Horse of the Vaccine Race May Be This French Biotech
Valneva shot is Europe’s only inactivated vaccine in trials
This article is for subscribers only.
As the battle with Covid-19 rages around the world, a small French biotech has a possible solution for the long-term war against the virus and the rapidly spreading mutations.
The company, Valneva SE, has a vaccine that could be more variant-proof, giving it an edge over other shots in what may be an annual campaign against a disease that’s already killed more than 3 million people. The first participant in its phase three trials will be dosed this week. If successful, that could lead to an approved shot in the fall.